Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs

A technology of lactoferrin and therapeutic drugs, applied in the field of protein drugs, can solve the problem of no report on the efficacy of apo-lactoferrin in Parkinson's disease, and achieve the effect of treating or preventing Parkinson's disease

Inactive Publication Date: 2017-03-22
QINGDAO UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the curative effect of apolactoferrin for the treatment of Parkinson's disease in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs
  • Application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs
  • Application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0060] Methods: Our experimental animals were male C57BL / 6 mice after 10 weeks of birth. Body weight was recorded every day, and a pole climbing test was performed every other day. We performed immunohistochemical staining for non-heme iron in the substantia nigra, liver and spleen by iron staining and Prussian blue staining, and expression of tyrosine hydroxylase (TH) in the substantia nigra by immunofluorescence. The cells were stained, and the striatal dopamine (DA) content and its metabolites were measured by high performance liquid chromatography. Serum iron (SI), serum ferritin (SI) and total iron binding capacity (TIBC) were detected by ELISA. Western blot method was used to detect Lf, lactoferrin receptor (lactoferrin receptor, LfR), divalent metal ion transporter (divalent metal transporter, DMT1), membrane ferroportin (ferriportin1, Fpn1), Bcl-2, Bax and Expression of caspase-3 in the substantia nigra.

[0061] Lf alleviates MPTP-induced weight loss and behavioral...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of Lf (lactoferrin) in preparation of PD (Parkinson's disease) treating drugs. The drugs are used for treating or preventing a toxicological action of MPTP (1-methyl-4-phenyl-1,2 ,3 ,6-tetrahydropyridine), the Lf is APO-Lf or HOLO-Lf, the two drugs both can reduce the level of iron in substantia nigra in the brain and play a neuroprotective effect on a patient with PD, APO-Lf and HOLO-Lf have no influence on peripheral iron level, neither are chelated with iron to result in anemia, nor increase iron to cause iron loading. In one embodiment, the Lf is APO-Lf or HOLO-Lf.

Description

technical field [0001] The invention belongs to the field of protein medicine, and in particular relates to the application of lactoferrin in preparing Parkinson's treatment medicine. Background technique [0002] Parkinson's disease (PD) is a common degenerative disease of the central nervous system, and its clinical manifestations mainly include resting tremor, muscle stiffness, decreased movement, and postural reflex disorder. The neuropathological basis of PD is the degeneration and loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) and the resulting decrease in striatal DA content. The etiology of PD is not yet fully understood, but iron accumulation in the substantia nigra (SN) is considered to be involved in the pathogenesis of PD. The midbrain SNpc of PD patients has a large number of activated microglia, and these activated microglia and residual DA neurons have a large amount of iron deposition. However, the relationship between microglial ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/40A61P25/16
CPCA61K38/40
Inventor 王俊谢俊霞刘卉莹吴昊
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com